We evaluated the antileukemic efficacy of ME2 inhibitors EA (non-ionic form) and Na2EA (ionic form) in THP-1 and MV4-11 disseminated AML ASID mouse models (Fig. 6A). This evidence concerns the gene ME2 and acute myeloid leukemia.